Zobrazeno 1 - 10
of 68
pro vyhledávání: ''
Publikováno v:
OncoTargets and therapy
Cancer is one of the major threats to human health. Although humans have struggled with cancer for decades, the efficacy of treatments for most tumors is still very limited. Dihydroartemisinin (DHA) is a derivative of artemisinin, a first-line antima
Autor:
Ting Lei, Tong Zhao, Ruoyu Wang, Bin Yang, Yan Ding, Yuqin Tian, Bowen Tan, Xinjia Ding, Lin Liu, Jianlin Wu
Publikováno v:
OncoTargets and therapy
Multiple primary cancers (MPC) occurring in the same individual is considered rare but being increasingly recognized owing to the longer cancer survival nowadays. Despite of accumulating experience in diagnosis, effective treatment remains to be prob
Autor:
Jae Il Chung, Young Joo Park, Wansuk Kim, Won Ik Seo, Tae Yong Park, Ja Yoon Ku, Hong Koo Ha, Chan Ho Lee
Publikováno v:
Journal of Chemotherapy. 33:245-255
Targeted therapy for metastatic renal cell carcinoma (mRCC) treatment requires the identification of clinically important factors that can predict the therapeutic effect. We retrospectively investigated the prognostic roles of pre-treatment sarcopeni
Publikováno v:
OncoTargets and therapy
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor, and surgical resection is the first choice for the treatment of the disease, but since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib (IM), the prognosis of
Autor:
Qiang Zhang, Shi Xin Yan, Ying Ying Cheng, Hui Li, Zhicheng Huang, Ying Liu, Jinhua Xu, Shaowei Lan
Publikováno v:
OncoTargets and therapy
Purpose The rearrangement of ROS1 (C-ros oncogene 1) is an important driver of non-small cell lung cancer (NSCLC). Currently, only approximately 24 ROS1 fusion partners have been shown to be sensitive to crizotinib. Although fusion partner determinat
Publikováno v:
OncoTargets and therapy
Background Overexpression of human epidermal growth factor receptor 2 (HER2) is associated with aggressive disease and poor prognosis. Traditional HER2-targeted agents can improve clinical outcome and have played an essential role in therapy. Pyrotin
Autor:
David Robinson, Christine Davis, Matthew Turnure, Stephanie Hawthorne, Otavio Clark, Gena Kanas, Madelyn Hanson, Linda Zhao
Publikováno v:
Cancer Management and Research. 12:5633-5639
Context Melanoma treatment has substantially changed over the last several years, yet little information regarding physician's preferences around treatment exists. Objective Our aim is to describe the results of the CancerMPact (CMP) survey performed
Publikováno v:
Cancer Management and Research. 12:4453-4460
Background Lung cancer has the highest incidence among solid tumors in men and is the third most common cancer in women. Despite improved understanding of genomic and mutational landscape in non-small cell lung cancer (NSCLC), the five-year survival
Publikováno v:
OncoTargets and Therapy. 13:4249-4255
Purpose HER2 overexpression has been identified in approximately 14% of bladder adenocarcinomas. However, until now, there has been no approved standard targeted therapy for bladder adenocarcinoma patients harboring HER2 genetic alteration. Case pres
Publikováno v:
OncoTargets and Therapy. 13:2689-2699
Aim This study aimed to investigate the effect of HOTTIP and miR-137 on cisplatin resistance of pancreatic cancer cells, and study the mechanism of the effect of HOTTIP on the resistance to cisplatin in pancreatic cancer cells, so as to provide new t